PEGylated liposomes (PEG-liposomes) + reovirus (pelareorep)
Combination therapy using reovirus and immune checkpoint inhibitors has shown promising results in clinical studies against several types of tumors. Third, reovirus downregulates the expression of hypoxia inducible factor-1α (HIF-1α), a transcriptional factor that is highly involved not only in the growth and survival of tumor cells under hypoxic conditions, but also in the production of extracellular matrices in tumors, leading to alteration of tumor microenvironments
PEG-liposomes, particularly their delivery inside the tumors, is often disturbed by physical barriers in the tumor, including tumor cells themselves, extracellular matrices, and interstitial pressures.
Results demonstrated that pretreatment with reovirus significantly improved the tumor disposition and intratumoral distribution pattern of subsequently administered PEG-liposomes in subcutaneous tumor-bearing subjects.
https://www.sciencedirect.com/science/article/abs/pii/S0168365922008641